In the BioHarmony Drug Report Database

"Preview" Icon

Selumetinib

Koselugo (selumetinib) is a small molecule pharmaceutical. Selumetinib was first approved as Koselugo on 2020-04-10. It is used to treat neurofibromatosis 1 in the USA. The pharmaceutical is active against dual specificity mitogen-activated protein kinase kinase 1 and dual specificity mitogen-activated protein kinase kinase 2. In addition, it is known to target serine/threonine-protein kinase B-raf. Koselugo’s patents are valid until 2026-12-12 (FDA).

 

Trade Name

 

Koselugo
 

Common Name

 

selumetinib
 

ChEMBL ID

 

CHEMBL1614701
 

Indication

 

neurofibromatosis 1
 

Drug Class

 

Tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors

Image (chem structure or protein)

Selumetinib structure rendering